Skip to content

Released May 6, 2021, after the close

10-Q filed May 7, 2021, 37 days after period end · 0001628280-21-009552

Q1 2021 · 10-Q
Revenue$32.79M+18.7% vs Q1 2020−26.5% vs Q4 2020
Net Income-$18.82MN/M vs Q1 2020N/M vs Q4 2020
EPS Diluted-$0.25N/M vs Q1 2020N/M vs Q4 2020
Operating Income-$19,320,000N/M
Operating Cash Flow-$12,901,000N/M
Free Cash Flowderived-$19,824,000N/M
Margins · derived
Operating margin-58.9%−4.8 pt vs Q1 2020
Net margin-57.4%+0.5 pt vs Q1 2020

What the release said

The release

Same quarter

MetricQ1 2021Q1 2020Q1 2019Q1 2018
Revenue$32.79M$27.62M$30.11M$25.25M
Net Income-$18.82M-$15.98M-$25.47M-$13.25M
EPS Diluted-$0.25-$0.23-$0.44-$0.34

The same fiscal quarter, prior years. Thaler holds no estimates to compare against.

Standard Biotools Inc. · CIK 1162194 · Engraved from SEC EDGAR